The story of Sildenafil presents a challenging picture for investors. While the initial release generated significant profits, the expiration of its exclusive rights opened the door to cheaper versions, dramatically reducing sales. This creates a particular dilemma for firms banking on comparable blockbuster medications, suggesting that a blind par

The legacy of Viagra, and its developer copyright, presents a challenging case study for investors. Originally a blockbuster drug, generating billions in sales , its exclusivity period created a deluge of knock-off medications, significantly eroding its market share . While specific businesses may attempt to capitalize on similar conditions , the e